Cancer Communications
indexed by SCI
BMC

doi: 10.5732/cjc.011.10149
Long-term molecular changes in WHO grade II astrocytomas following radiotherapy
Wei-Ying Yue, Ke Sai, Qiu-Liang Wu, Yun-Fei Xia, Su-Huan Yu, Zhong-Ping Chen
State Key Laboratory of Oncology in South China; Department of Neurosurgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China
[Abstract] Monitoring the long-term radiotherapy-associated molecular changes in low-grade gliomas (LGGs) facilitates the understanding of LGG response to radiotherapy. In this study, we used immunohistochemistry to analyze the expression of Ki-67, tumor protein P53 (TP53), P21, and P27 in 8 paired WHO grade II astrocytoma samples. The interval between radiotherapy (RT) and the second surgery was more than 3 months in all cases. The average Ki-67 labeling index (LI) was 5.3% in pre-RT samples and 11.54% in post-RT samples. Ki-67 LI was higher in the primary tumors that underwent malignant transformation observed at the second surgery after radiation. Post-RT Ki-67 LI decreased in 2 cases with an interval of less than 12 months between RT and the second surgery. TP53 expression was found in 3 out of 4 pre-RT samples with malignant transformation and in 1 out of 4 pre-RT samples without malignant transformation. Post-RT TP53 increased in 2 cases in which increased expression of P21 or P27 was also observed. Our study suggests that radiotherapy can inhibit WHO grade II astrocytoma proliferation as reflected by Ki-67 LI, but the effect attenuates with time. In addition, there is a tendency of malignant transformation for WHO grade II astrocytomas with a high Ki-67 level or TP53 expression in initial samples.
Chinese Journal of Cancer 2012, Volume: 31, Issue 3, Page: 159-165
[ PDF Full-text ]
[ Html full-text ](PubMed Central)

[ PubMed ]

[Google Scholar]


Cite this article

Wei-Ying Yue, Ke Sai, Qiu-Liang Wu, Yun-Fei Xia, Su-Huan Yu, Zhong-Ping Chen. Long-term molecular changes in WHO grade II astrocytomas following radiotherapy. Chin J Cancer. 2012, 31(3):159-165. doi:10.5732/cjc.011.10149


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China